股市必读：塞力医疗三季报 - 第三季度单季净利润同比增长39.27%

Core Viewpoint - The financial performance of Sely Medical (603716) has significantly declined in the first three quarters of 2025, with a notable drop in both revenue and net profit, leading to a negative outlook for the company [1][3]. Trading Information Summary - On October 29, 2025, Sely Medical's stock closed at 24.3 yuan, down 0.25%, with a turnover rate of 4.51% and a trading volume of 94,700 shares, resulting in a transaction amount of 230 million yuan [1]. - The main funds experienced a net outflow of 38.52 million yuan, accounting for 16.77% of the total transaction amount, while retail investors saw a net inflow of 48.24 million yuan, representing 21.01% of the total [1][3]. Financial Report Summary - For the first three quarters of 2025, Sely Medical reported a main revenue of 857 million yuan, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [1]. - In Q3 2025, the company recorded a single-quarter main revenue of 274 million yuan, a decline of 38.41% year-on-year, and a net profit of -31.12 million yuan, which is an increase of 39.27% compared to the previous quarter [1]. - The company’s debt ratio stands at 49.61%, with investment income of 7.34 million yuan and financial expenses of 349.82 million yuan, resulting in a gross profit margin of 21.73% [1]. Company Announcement Summary - On October 29, 2025, Sely Medical held the 22nd meeting of the fifth board of directors, where all nine directors were present, and no votes were against or abstained [2]. - The board approved the Q3 2025 report and the proposal for asset impairment preparation, both of which had been previously reviewed by the audit committee [2][3].